Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have achieved acknowledged progress in cancer therapy. However, ICI-associated cardiotoxicity as one of the most severe adverse events is potentially life-threatening, with limited real-world studies reporting its predictive factors and prognosis. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xue, Jiang, Aimin, Zhang, Rui, Fu, Xiao, Liu, Na, Shi, Chuchu, Wang, Jingjing, Zheng, Xiaoqiang, Tian, Tao, Liang, Xuan, Ruan, Zhiping, Yao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163804/
https://www.ncbi.nlm.nih.gov/pubmed/35669482
http://dx.doi.org/10.3389/fcvm.2022.882167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163804/
https://www.ncbi.nlm.nih.gov/pubmed/35669482
http://dx.doi.org/10.3389/fcvm.2022.882167

Ejemplares similares